Role of microRNAs in glioblastoma

Ming Chen, Zdravka Medarova and Anna Moore _

PDF  |  Full Text  |  How to cite

Oncotarget. 2021; 12:1707-1723. https://doi.org/10.18632/oncotarget.28039

Metrics: PDF 1478 views  |   Full Text 4931 views  |   ?  


Ming Chen1,2, Zdravka Medarova3 and Anna Moore1,2

1 Precision Health Program, Michigan State University, East Lansing, MI 48824, USA

2 Department of Radiology, College of Human Medicine, Michigan State University, East Lansing, MI 48824, USA

3 Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA

Correspondence to:

Anna Moore, email: [email protected]

Keywords: glioblastoma; microRNA; miRNA-based therapies; miRNA delivery

Received: May 04, 2021     Accepted: July 27, 2021     Published: August 17, 2021

Copyright: © 2021 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Glioblastoma is the most common and aggressive primary human brain cancer. MicroRNAs (miRNAs) are a set of small endogenous non-coding RNA molecules which play critical roles in different biological processes including cancer. The realization of miRNA regulatory functions in GBM has demonstrated that these molecules play a critical role in its initiation, progression and response to therapy. In this review we discuss the studies related to miRNA discovery and function in glioblastoma. We first summarize the typical miRNAs and their roles in GBM. Then we debate the potential for miRNA-based therapy for glioblastoma, including various delivery strategies. We surmise that future directions identified by these studies will point towards the necessity for therapeutic development and optimization to improve the outcomes for patients with glioblastoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28039